Brief: Poxel Announces Positive Pharmacokinetic/Pharmacodynamic Study Results For Pxl770

Poxel SA

24/06/2020 07:07

June 24 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL ANNOUNCES POSITIVE PHARMACOKINETIC (PK) /
PHARMACODYNAMIC
(PD) STUDY RESULTS FOR PXL770, A DIRECT AMPK ACTIVATOR FOR THE
TREATMENT OF NASH
    * STUDY MET ITS KEY OBJECTIVES
    * PXL770 WAS OBSERVED TO DEMONSTRATE A CONSISTENT PK PROFILE
IN
LIKELY-NASH PATIENT POPULATION AND WAS OBSERVED TO BE SAFE AND
WELL-TOLERATED
    * EFFICACY AND SAFETY RESULTS FROM PXL770 PHASE 2A STUDY FOR
TREATMENT OF NASH ARE ANTICIPATED LATE Q3 2020
    * RESULTS DEMONSTRATE TARGET ENGAGEMENT AND EFFICACY SIGNALS
THAT
SUPPORT POTENTIAL FOR PXL770 IN NASH AND FOR AMPK PLATFORM IN
OTHER CHRONIC AND RARE METABOLIC DISEASES

Source text for Eikon:  ID:nBw446G27a 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))